3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
40
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
32
Leukemia
17
Leukemia, Myeloid, Chronic-Phase
16
Leukemia, Myeloid, Acute
14
Breast Neoplasms
12
Recurrence
11
Leukemia, Lymphocytic, Chronic, B-Cell
10
Prostatic Neoplasms
9
Neoplasm Metastasis
9
Carcinoma, Non-Small-Cell Lung
9
Lung Neoplasms
7
Blast Crisis
7
Pancreatic Neoplasms
6
Burkitt Lymphoma
6
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
5
Neoplasms
5
Multiple Myeloma
5
Lymphoma, Non-Hodgkin
5
Glioma
5
Glioblastoma
5
Philadelphia Chromosome
4
Myelodysplastic Syndromes
4
Lymphoma, Large B-Cell, Diffuse
4
Lymphoma
4
Leukemia, Myeloid, Accelerated Phase
4
Gliosarcoma
4
Gastrointestinal Stromal Tumors
4
Colorectal Neoplasms
4
Waldenstrom Macroglobulinemia
3
Interventions
nilotinib
1
Dasatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Substance Withdrawal Syndrome
×
Dasatinib
×
Clear all
NCT04147533
2024-11-26
HALF
Masaryk University
Phase 2
Active not recruiting
150 enrolled